Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING
RANDOX LABORATORIES

Lung Biopsies Reduced by Panel of Serum Biomarkers

By Labmedica International staff writers
Posted on 04 Apr 2012
A panel of serum biomarkers could help predict the level of lung cancer risk in high-risk patients, offering doctors an option before proceeding with a biopsy.

The panel of protein biomarkers could help in lung cancer diagnosis as given the substantial risks of invasive diagnostic thoracic procedures, and unselective biopsy of every person with a small nodule is clinically undesirable.

A multicenter team, led by scientists at the University of Pittsburgh Cancer Institute (PA, USA), identified candidate serum biomarkers in a training set of sera from 56 patients with biopsy-proven primary non-small-cell lung cancer and 56 age-, sex-, and smoking-matched controls. They measured 70 cancer-related proteins by Luminex xMAP multiplexed immunoassays. The classification performance of the 10-biomarker panel was also analytically validated using enzyme-linked immunosorbent assays (ELISA) in a second independent case/control population, further validating the robustness of the panel.

The scientists identified a panel of 10 serum biomarkers including prolactin, transthyretin, thrombospondin-1, E-selectin, C-C motif chemokine 5, macrophage migration inhibitory factor, plasminogen activator inhibitor, receptor tyrosine-protein kinase, cytokeratin fragment 21.1, and serum amyloid A, which distinguished lung cancer patients from controls. The xMAP-multiplexed immunoassays are products of Luminex (Austin, TX, USA).

The ELISA kits for human thrombospondin-1, plasminogen activator inhibitor (PAI-1 and SERPINE1), and macrophage migration inhibitory factor (MIF), are products of R&D Systems (Minneapolis, MN, USA). ELISA kits for carcinoembryonic antigen (CEA), receptor tyrosine-protein kinase 2, and transthyretin (TTR) are manufactured by Immunology Consultants Laboratory, (Minneapolis, MN, USA), Calbiochem (Gibbstown, NJ, USA), and ALPCO (Salem, NH, USA), respectively.

The authors concluded that although the biomarker model they described could not detect every lung cancer, it offers a significant clinical improvement over computed tomography (CT) imaging alone. According to the study, about 20% of the 1-2 cm nodules that are concerning enough to be considered for biopsy are actually malignant, but those who are identified by small pulmonary nodules can be correctly classified by the study's model. The article was published in the April 2012 issue of the Journal of Thoracic Oncology.

Related Links:

University of Pittsburgh Cancer Institute
Luminex
R&D Systems




DiagCor Bioscience
Sekisui Diagnostics
VIRCELL
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.